drugset / Trial / NCT00686543

Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)

NCT00686543

Phase 4 Completed 75 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is: to explore the potential for different dosing strategies of posaconazole oral suspension (POS) to increase plasma levels and to profile the pharmacokinetics of these dosing strategies in patients with compromised gastrointestinal function and at high risk for Invasive Fungal Infection.

Timeline

Start
2007-12
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Posaconazole Small molecule 200 mg Oral
Subject Posaconazole Small molecule 400 mg Oral